Evaluation of the Role of LcrV-Toll-Like Receptor 2-Mediated Immunomodulation in the Virulence of Yersinia pestis

Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA.
Infection and Immunity (Impact Factor: 3.73). 08/2007; 75(7):3571-80. DOI: 10.1128/IAI.01644-06
Source: PubMed


Pathogenic members of the Yersinia genus require the translocator protein LcrV for proper function of the type III secretion apparatus, which is crucial for virulence. LcrV has also been reported to play an independent immunosuppressive role via the induction of interleukin-10 (IL-10) through stimulation of Toll-like receptor 2 (TLR2). To investigate the LcrV-TLR2 interaction in vitro, His-tagged recombinant LcrV (rLcrV) from Yersinia pestis was cloned and expressed in Escherichia coli and purified through Ni-nitrilotriacetic acid column chromatography. High concentrations (5 microg/ml) of rLcrV stimulated TLR2 in vitro. Fractionation of rLcrV preparations via gel filtration revealed that only a minor component consisting of high-molecular-weight multimers or aggregates has TLR2 stimulating activity. Dimer and tetramer forms of rLcrV, which constitute the bulk of the material, do not have this activity. To investigate the potential role of LcrV/TLR2 in plague pathogenesis, we infected wild-type and TLR2(-/-) mice with virulent Y. pestis. No discernible difference between the two mouse strains in severity of disease or kinetics of survival after subcutaneous challenge was observed. IL-6, tumor necrosis factor, and IL-10 levels from spleen homogenates; bacterial load; and the extent of inflammation observed in organs from mice infected intravenously were also indistinguishable in both mouse strains. Taken together, our data indicate that the most abundant molecular species of Y. pestis LcrV do not efficiently activate TLR2-signaling and that TLR2-mediated immunomodulation is unlikely to play a significant role in plague.

Download full-text


Available from: Shan Lu
  • Source
    • "Previous results were essentially the same when the mice in the same vaccination groups were challenged with half the dose (10 LD 50 ) of Y. pestis CO92 except all (10/10) the F1-V vaccinated C3H/HeJ Tlr4 mutant mice survived. that the host's immune system is being compromised [28]. Although we did not include a Myd88 deficient group that received only adjuvant, we believe that like the wild-type C57BL/6 mice that received only adjuvant, this group would "
    [Show abstract] [Hide abstract]
    ABSTRACT: The current candidate vaccine against Yersinia pestis infection consists of two subunit proteins: the capsule protein or F1 protein and the low calcium response V protein or V-antigen. Little is known of the recognition of the vaccine by the host's innate immune system and how it affects the acquired immune response to the vaccine. Thus, we vaccinated Toll-like receptor (Tlr) 2, 4, and 2/4-double deficient, as well as signal adaptor protein Myd88-deficient mice. We found that Tlr4 and Myd88 appeared to be required for an optimal immune response to the F1-V vaccine but not Tlr2 when compared to wild-type mice. However, there was a difference between the requirement for Tlr4 and MyD88 in vaccinated animals. When F1-V vaccinated Tlr4 mutant (lipopolysaccharide tolerant) and Myd88-deficient mice were challenged by aerosol with Y. pestis CO92, all but one Tlr4 mutant mice survived the challenge, but no vaccinated Myd88-deficient mice survived the challenge. Spleens from these latter nonsurviving mice showed that Y. pestis was not cleared from the infected mice. Our results suggest that MyD88 appears to be important for both an optimal immune response to F1-V and in protection against a lethal challenge of Y. pestis CO92 in F1-V vaccinated mice.
    Full-text · Article · Jun 2014 · Research Journal of Immunology
  • Source
    • "However, the F1-minus strains of YP are highly virulent, and different strains of this pathogen might have variants of LcrV (Smiley 2008a; Titball and Williamson 2004). Further, full-length LcrV might be immunosuppressive in nature and cause Th2 cytokine polarization (Murphy et al. 2007), although several studies have suggested the contrary (Reithmeier-Rost et al. 2007; Pouliot et al. 2007). Therefore, such F1–LcrV-based vaccines might not be optimal. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Yersinia pestis (YP), the gram-negative plague bacterium, has shaped human history unlike any other pathogen known to mankind. YP (transmitted by the bite of an infected flea) diverged only recently from the related enteric pathogen Yersinia pseudotuberculosis but causes radically different diseases. Three forms of plague exist in humans: bubonic (swollen lymph nodes or bubos), septicemic (spread of YP through the lymphatics or bloodstream from the bubos to other organs), and contagious, pneumonic plague which can be communicated via YP-charged respiratory droplets resulting in person-person transmission and rapid death if left untreated (50-90% mortality). Despite the potential threat of weaponized YP being employed in bioterrorism and YP infections remaining prevalent in endemic regions of the world where rodent populations are high (including the four corner regions of the USA), an efficacious vaccine that confers immunoprotection has yet to be developed. This review article will describe the current vaccine candidates being evaluated in various model systems and provide an overall summary on the progress of this important endeavor.
    Full-text · Article · Jun 2011 · Applied Microbiology and Biotechnology
  • Source
    • "V antigen upregulates anti-inflammatory cytokine, IL-10, and represses the host proinflammatory cytokines including IFN-␥ and TNF-␣ 16—19. This reaction is mediated by TLR2 20—23 or receptor bound human IFN-␥ at dual binding sites [24], however TLR2 stimulating activity in vitro is restricted to high-molecular-weight aggregates/multimers of V antigen [25]. In spite of possessing immunomodulatory properties, it has been shown that V antigen is a protective antigen which stimulates humoral and cellular immune response in experimental animals that afford protection against plague infection 26—29. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Yersinia pestis is a Gram negative bacterium which causes bubonic and pneumonic plague. Out of the two protective antigens F1 and V as vaccine candidates, we focused our attention on V antigen as peptide-based immunogen. Eleven peptides of varying lengths were synthesized for mapping major antigenic sites on V antigen. Six peptides showed competition by three complimentary approaches (1) with anti-V sera, (2) with anti-peptide sera and (3) by direct binding assay. Peptides which showed competition were found to be highly immunogenic in terms of peak antibody titres (both IgG and IgA) with longer duration, showed predominantly IgG2a/IgG2b subclass distribution, high affinity/avidity indices with single immunization schedule through intranasal routes. After intranasal immunization, these peptides showed high IgA response in sera and SIgA in intestinal washes and bronchoalveolar lavages while intramuscular immunization failed to give mucosal response. Intramuscular immunization generated high titre antibodies (both IgG and IgA) in sera with negligible SIgA response in washes which required additional booster immunization. All the peptides sera reacted with V antigen in Western blot analysis. During T cell proliferation assay, five peptides showed lymphocyte proliferation response irrespective of how antigen priming and pulsing was done in three strains of mice. These five peptides also showed Th1 cytokine profile whereas rest of the peptides showed mixed Th1/Th2 response. Two peptides exclusively showed high levels of IL-10 production. Mathematical modeling of V antigen indicates that these peptides lie on the surface of the protein. In conclusion, peptides a, g and j are pure B cell epitopes; peptides d and k are pure T cell epitopes and peptides b, f and i showed both B and T cells property on V antigen.
    Full-text · Article · Feb 2008 · Vaccine
Show more